GLP1R and type 2 diabetes mellitus: <h4>Introduction</h4>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are therapies for type 2 diabetes whose use expanded sharply after semaglutide's 2021 approval for obesity.